Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Ertugliflozin, Sitagliptin | Steglujan | 4.5. Interactions with other medicinal products | Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations | Oct,2022 |
| Ertugliflozin, Metformin Hydrochloride | Segluromet | 4.5. Interactions with other medicinal products | Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations | Oct,2022 |
| Ertugliflozin | Steglatro | 4.5. Interactions with other medicinal products | Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations | Oct,2022 |
| Canagliflozin | Invokana | 4.5. Interactions with other medicinal products | Lithium: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently during INVOKANA initiation and dosage changes. | Oct,2022 |
| Topiramate | Topamax | 4.4. Special warnings and precautions for use | Kidney Stones | Oct,2022 |
| Dolutegravir, Lamivudine | Dovato | 4.8. Undesirable effects | Creatinine phosphokinase elevation | Oct,2022 |